MedTrace Logo

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

NCT02283814 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-04-11

Study results available
· View outcomes & findings →

Summary

Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers

Conditions

Interventions

DRUG

BIA 2-093

DRUG

Topamax

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-02-28
Completion
2007-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02283814 on ClinicalTrials.gov